Almost 7 years removed from the first FDA approved Biosimilar (Zarxio) in 2015, the US market for Biosimilars is projected to be highly beneficial over the next decade, for both pharmaceutical companies as well as patients, with RAND Corporation projecting estimated savings of over $54 Billion during this period. To truly comprehend such forecasts, a deeper understanding of what constitutes a ‘Biosimilar Drug’ is required. Essentially, the structure of a biosimilar is based on a pre-existing, approved drug known as a Biologic & possesses no significant clinical difference in safety,…
Read MoreTag: Pharma
Discussing ‘Reducing Errors at Point-Of-Care’ with Uchenna Okeahiala of Airedale and Bradford Hospitals Integrated Pathology Solutions, UK .
Graduated from University of Nigeria with a bachelor’s degree in Biomedical Sciences in 1989, Uchenna started her career as a Biomedical Scientist in Nigeria She relocated to the United Kingdom in 1991 where she obtained her Master’s degree in Biomedical Sciences from University of Cardiff with a Distinction in 1996 and went on to score a certificate in management from the Open University (1999). Later in 2006, she obtained a certificate in Extended Practice in Quality Management with Institute of Biomedical Sciences (IBMS). Since then has worked in various NHS…
Read MoreTechnologies Transforming Real-World Evidence (RWE) Evidence in the Pharmaceutical Industry
As new drugs are emerging every day, it is very important to ensure that the patients get right and effective treatment. One such step can be taken from Real World Evidence (RWE). In simple words, Real World Evidence means data and information collected outside of a clinical trial. This data can be electronic medical records, medical charts or other medical claims to assess patient outcomes. It is made sure that the patient’s identity is removed from the previous data to maintain the patient’s privacy. However, today’s real-world evidence data is…
Read More